Peptide Initiative

Peptides · Peptide comparison

Capromorelin vs CJC-1295 with DAC

An oral ghrelin agonist originally developed by Pfizer that stimulates growth hormone and appetite. FDA-approved for veterinary use (Entyce and Elura) and investigated in human trials for age-related muscle wasting and appetite support.

Long-acting growth hormone releaser that works around the clock to boost your body's natural GH production with just one or two injections per week.

  • Growth Hormone
  • Growth Hormone

At a glance

Quick comparison

Dose rangeCapromorelin10–10 mgCJC-1295 with DAC2–2 mg
FrequencyCapromorelinOnce dailyCJC-1295 with DACTwice weekly
AdministrationCapromorelinOral (capsule or tablet)CJC-1295 with DACSubcutaneous injection
Cycle lengthCapromorelin4-6 weeksCJC-1295 with DAC8-12 weeks
Onset speedCapromorelinModerate (1-2 weeks)CJC-1295 with DACModerate (1-2 weeks)
Evidence levelCapromorelinModerate human trials (Phase 1-2)CJC-1295 with DACModerate human trials (Phase 1-2)

Efficacy

Benefit ratings

GH & IGF-1 Stimulation

Capromorelin88%
CJC-1295 with DACNo recorded rating

Physical Function

Capromorelin82%
CJC-1295 with DACNo recorded rating

Oral Convenience

Capromorelin92%
CJC-1295 with DACNo recorded rating

GH Elevation

CapromorelinNo recorded rating
CJC-1295 with DAC92%

Convenience

CapromorelinNo recorded rating
CJC-1295 with DAC95%

Recovery Support

CapromorelinNo recorded rating
CJC-1295 with DAC88%

Technical data

Compound specifications

Capromorelin

Molecular formula
C28H35N5O4
Molecular weight
505.6 g/mol
Half-life
About 1.2 hours in dogs (ENTYCE label)
Bioavailability
44% oral in dogs and 65% in rats; no human figure published on this page
CAS number
193273-66-4

CJC-1295 with DAC

Molecular formula
C165H269N47O46
Molecular weight
3647.28 g/mol
Half-life
6-8 days
Bioavailability
~100% (subcutaneous)
CAS number
863288-34-0

Protocols

Dosing compared

Capromorelin

Oral

  • 3 mgTwice daily · Initial weeksOne of the lower doses tested in the year-long study in older adults; raised growth hormone and IGF-1 [1].
  • 10 mgOnce daily at bedtime · OngoingA simple once-daily bedtime dose used in the human trial that improved lean body mass [1].
  • 10 mgTwice daily · Up to 12 months in the trialThe highest daily amount studied in older adults (20 mg/day). The trial reported results for the pooled treatment groups, not the largest gains for this dose [1].

CJC-1295 with DAC

Subcutaneous

  • 1 mg (1000 mcg)Once weekly · 2-4 weeksA starting dose used in practice. The DAC version is long-acting (about a 6-8 day half-life), so weekly dosing keeps growth hormone and IGF-1 raised. In the Phase 1 trial a single dose raised GH for 6+ days and IGF-1 for up to 11 days. [2]
  • 2 mg (2000 mcg)Once weekly (or split twice weekly) · 8-12 weeksThe common maintenance dose, roughly in line with the 30-60 mcg/kg weekly range studied in the Phase 1 trial. [1][2] In the ascending-dose trials, single injections raised mean GH 2- to 10-fold for six or more days and IGF-I 1.5- to 3-fold for 9-11 days; 30 and 60 µg/kg doses were the best tolerated [2].
  • 2 mg per doseTwice weekly · 8-12 weeksA higher total weekly amount split into two doses, used by experienced users; near the top of the 30-60 mcg/kg weekly range from the clinical study. [2]

Applications

Best suited for

Capromorelin

Age-Related Muscle Wasting
Capromorelin showed significant improvements in physical function — including tandem walk and stair climb — in elderly adults, making it a strong candidate for combating sarcopenia.
Appetite Stimulation
As an FDA-approved veterinary appetite stimulant, capromorelin has extensive real-world evidence for boosting food intake and body weight in mammals.
Growth Hormone Research
One of the best-studied oral ghrelin agonists with human Phase 2 data, offering researchers a well-characterized tool for studying GH/IGF-1 pathways.

CJC-1295 with DAC

Growth Hormone Optimization
CJC-1295 with DAC excels at providing a sustained, steady elevation of growth hormone levels. Unlike shorter-acting peptides that create brief spikes, the DAC modification keeps GH elevated for days, mimicking a more youthful hormone profile.
Muscle Building and Recovery
By increasing both GH and IGF-1 levels, this peptide supports protein synthesis and muscle repair. Users often notice improved recovery between workouts and better ability to build and maintain lean muscle mass.
Anti-Aging and Longevity
Growth hormone naturally declines with age, contributing to many signs of aging. CJC-1295 with DAC helps restore more youthful GH levels, potentially supporting better skin quality, energy levels, and overall vitality.
Body Composition Improvement
The combination of increased GH and IGF-1 promotes fat metabolism while preserving muscle tissue. Many users experience gradual fat loss, particularly in stubborn areas, while maintaining or building lean mass.
Convenient Weekly Dosing
Unlike peptides requiring daily or twice-daily injections, the extended half-life of CJC-1295 with DAC means just one or two injections per week provide continuous benefits. Ideal for those who want results without daily protocols.

Safety profile

Side effects

Capromorelin

Common

  • Appetite stimulation
  • Fluid retention and weight gain

Uncommon

  • Joint and muscle aches
  • Fatigue or lethargy
  • Peripheral edema (swelling)

Serious

  • Hyperglycemia

CJC-1295 with DAC

Common

  • Injection site reactions
  • Water retention
  • Flushing
  • Tingling sensation

Uncommon

  • Headaches
  • Fatigue or lethargy
  • Joint discomfort

Serious

  • Carpal tunnel symptoms
  • Blood glucose elevation

Research status

Safety & evidence

Capromorelin

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Not approved for human use. FDA-approved for veterinary use only: ENTYCE (appetite stimulation in dogs, 2016) and ELURA (weight loss in cats with chronic kidney disease, 2020); both labels state "not for use in humans".
Safety overview
Capromorelin was generally well-tolerated in Phase 2 human trials involving nearly 400 elderly participants. Most side effects were mild to moderate. Its FDA-approved veterinary use provides additional long-term safety data in mammalian species.

Contraindications

  • Active cancer or history of cancer (GH may stimulate growth)
  • Uncontrolled diabetes or severe metabolic disorders
  • Severe liver or kidney disease
  • Pregnancy and lactation

CJC-1295 with DAC

Evidence level
Moderate human trials (Phase 1-2)
FDA status
Research compound
Safety overview
CJC-1295 with DAC was evaluated in Phase 1-2 human clinical trials where it demonstrated a generally favorable safety profile. The most common adverse events were mild injection site reactions including temporary pain, swelling, and redness. No serious adverse events were reported in the published clinical studies. The compound was being developed for HIV-associated lipodystrophy before the program was discontinued.

Contraindications

  • Active cancer or history of malignancy
  • Pregnancy or breastfeeding
  • Pituitary tumors or disorders
  • Diabetic retinopathy
  • Uncontrolled diabetes

Decision guide

Which is right for you?

Capromorelin

Choose Capromorelin if…

  • Stimulating growth hormone production in elderly adults
  • Supporting appetite and weight gain in wasting conditions
  • Improving muscle mass and physical performance
  • Anti-aging and longevity optimization

CJC-1295 with DAC

Choose CJC-1295 with DAC if…

  • Boosting natural growth hormone production
  • Building lean muscle mass
  • Improving body composition
  • Anti-aging and longevity